Roche nabs European OK for Rituxan heir Gazyvaro; GSK dividend probably safe, analysts say;

@FiercePharma: Why are Anoro & Breo slow starters? GSK's new quota-free model, critics say. More | Follow @FiercePharma

@TracyStaton: On Pfizer, the market's focus is on EPS beat. 58 cents vs. expected 57. Shares up 1.3% pre-market. Release | Follow @TracyStaton

@EricPFierce: Impax shares take a thrashing after FDA issues Taiwan plant new Form 483 with 10 observations. Article | Follow @EricPFierce

@CarlyHFierce: Merck spokeswoman: Sales layoffs to hit PA-based field reps. Story | Follow @CarlyHFierce

> Roche ($RHHBY) won European approval for its chronic lymphocytic leukemia treatment, Gazyvaro, in another step toward turning the drug into a blockbuster successor to Rituxan. Release | Report (sub. req.)

> Despite GlaxoSmithKline's ($GSK) disappointing second-quarter results, analysts figure that its dividend is likely safe, at least for now. Report

> Ranbaxy Laboratories suffered a quarterly loss after yet another import ban because of quality problems at an Indian plant. Report

> Recent hedge fund filings show that U.S. drugmaker Bristol-Myers Squibb ($BMY) has fans in that slice of the investment world. Report

> Italy's Recordati boosted profits by 18% in the first half of 2014, thanks to a 6% increase in sales, to €507.6 million. Report

> Brazilian drugmaker Hypermarcas doesn't see any ripe opportunities for dealmaking, CEO Claudio Bergamo says. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Google wearables to add to planned bioinformatics database. Article | Follow @FierceMedDev

@StacyALawrence: Medtronic teaming up with China's LifeTech to develop cardiovascular products. More | Follow @StacyALawrence

@VarunSaxena2: FDA final guidance modifies 510(k) rules, discourages use of multiple predicate devices. Story | Follow @VarunSaxena2

@MichaelGFierce: Scientists test a Nanoparticle "Alarm Clock" to Awaken Immune Systems Put to Sleep by Cancer. More from Newswise | Follow @MichaelGFierce

@EmilyWFierce: FDA and physicians question the validity of popular mobile medical health apps. More from Wired | Follow @EmilyWFierce

> Wearable optical device detects diabetic complication. More

> Proteus Digital adds $52M to Series G, bringing total to $172M. News

> French devicemaker faces FDA scrutiny for prostate cancer device. Article

Biotech News

@FierceBiotech: Nominations are open for our 2014 Women in Biotech report. More | Nomination form | Follow @FierceBiotech

@JohnCFierce: Resurgent Merck to accelerate R&D spending in H2, hunt new drug deals. Article | Follow @JohnCFierce

@DamianFierce: $GSK has launched Tanzeum (albiglutide) in the U.S., further crowding the GLP-1 market for T2 diabetes. Press release | Follow @DamianFierce

@EmilyMFierce: Really cool, albeit potentially terrifying: Teeth Sprout from Glia-Derived Stem Cells. GEN piece | Follow @EmilyMFierce

> Pfizer, Lilly and J&J chip in on $51M seed fund for New York biotechs. News

> Targacept's litany of trial failures continues with yet another flop. Article

> Sanofi dumps KaloBios' antibiotic in another stinging setback. More

Biotech Research News

> NIH to spur innovation in new therapeutic areas. News

> Janssen rethinks drug discovery in a changing R&D environment. More

> Anti-inflammatory drug stops Parkinson's neuron loss in rats. Article

> CDC takes steps to improve lab safety after anthrax, flu scares. Story

> Vaccine protects animals against dust mite allergies. Item

Pharma Manufacturing News

> Impax now faces FDA issues at Taiwan plant that could affect Rytary. Report

> PCI buys contract manufacturer Penn Pharma in $215M deal. Story

> Merck KGaA to cut carbon dioxide emissions at Darmstadt site. More

> Hikma buys closed Boehringer plant and strips out equipment. News

> J&J done with Boehringer plant after building a supply of Doxil. Article

And Finally... The quantified-fitness company Jawbone launched an app to track caffeine consumption, UP Coffee. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.